ALTO-100 in MDD and/or PTSD
NCT05117632 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 245
Last updated 2023-12-01
Summary
The goal of this study is to collect biologically based data for defining predictors and correlates of the effects of ALTO-100.
Conditions
- Major Depressive Disorder
- Post Traumatic Stress Disorder
Interventions
- DRUG
-
ALTO-100 PO tablet
one tablet twice daily
Sponsors & Collaborators
-
Alto Neuroscience
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 69 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-12-20
- Primary Completion
- 2022-12-01
- Completion
- 2022-12-09
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Investigate Efficacy & Safety of RO4995819 vs. Placebo as Adjunct Tx in Patients w/Major Depressive Disorder
NCT01733654 ·Status: WITHDRAWN ·Phase: PHASE2
-
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
NCT05061706 ·Status: COMPLETED ·Phase: PHASE3
-
Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
NCT00761306 ·Status: COMPLETED ·Phase: PHASE2
-
An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
NCT05061719 ·Status: COMPLETED ·Phase: PHASE3
-
An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)
NCT04433858 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Open Label Extension Assessing the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder (MDD)
NCT00731653 ·Status: COMPLETED ·Phase: PHASE2
-
Safety of Liposom With Citalopram in Elderly Patients With Major Depressive Disorder
NCT04975724 ·Status: RECRUITING ·Phase: PHASE4
-
Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
NCT01179516 ·Status: COMPLETED ·Phase: PHASE3
-
A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD
NCT05414422 ·Status: COMPLETED ·Phase: PHASE2
-
ANC-501 in the Treatment of Adults With Major Depressive Disorder
NCT05439603 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression
NCT05018013 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study
NCT01152996 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
NCT01163266 ·Status: COMPLETED ·Phase: PHASE3
-
Open Trial of Escitalopram Treatment for Male Subjects With Posttraumatic Stress Disorder
NCT01024140 ·Status: COMPLETED ·Phase: NA
-
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
NCT03775200 ·Status: COMPLETED ·Phase: PHASE2
-
The Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression
NCT05762458 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)
NCT05081167 ·Status: COMPLETED ·Phase: PHASE3
-
Neurobiological Bases of Placebo Response in Major Depressive Disorder
NCT01787240 ·Status: TERMINATED ·Phase: PHASE4
-
An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression
NCT05660642 ·Status: RECRUITING ·Phase: PHASE2
-
Treatment of Depression in Adults
NCT00073697 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)
NCT00759395 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
NCT04985942 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Naltrexone-Induced Blockade of Antidepressant Effects
NCT04322526 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of ONO-1110 in Patients With Major Depressive Disorder
NCT06792136 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder
NCT00411099 ·Status: COMPLETED ·Phase: PHASE3